---
title: "Relamorelin"
canonical_url: https://peptidelibrary.app/library/relamorelin
description: "Investigational pentapeptide ghrelin receptor agonist developed principally for its gastrointestinal rather than endocrine effects. Ghrelin receptors on enteric neurons accelerate gastric emptying when activated, and relamorelin has been studied mainly in diabetic gastroparesis, where delayed emptying drives the symptoms. Clinical development has been mixed and it is not FDA-approved for any indication."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Relamorelin

Relamorelin (also called RM-131 or BIM-28131) is an investigational ghrelin analog in the Growth Hormone Secretagogue class. Relamorelin is a synthetic pentapeptide agonist at growth hormone secretagogue receptor 1a, developed principally for its gastrointestinal rather than endocrine activity. Ghrelin receptors are expressed on enteric neurons, and their activation accelerates gastric emptying and increases antral contractility.

Investigational pentapeptide ghrelin receptor agonist developed principally for its gastrointestinal rather than endocrine effects. Ghrelin receptors on enteric neurons accelerate gastric emptying when activated, and relamorelin has been studied mainly in diabetic gastroparesis, where delayed emptying drives the symptoms. Clinical development has been mixed and it is not FDA-approved for any indication.

Also known as: RM-131, BIM-28131, Ghrelin analog.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: Investigational ghrelin analog
- Mechanism class: Growth Hormone Secretagogue
- Development stage: In clinical development
- Regulatory class: Investigational, not FDA-approved

## Mechanism

Relamorelin is a synthetic pentapeptide agonist at growth hormone secretagogue receptor 1a, developed principally for its gastrointestinal rather than endocrine activity. Ghrelin receptors are expressed on enteric neurons, and their activation accelerates gastric emptying and increases antral contractility. Relamorelin was engineered for greater potency and metabolic stability than native ghrelin and has been studied in diabetic gastroparesis, where delayed gastric emptying underlies the symptoms. It raises growth hormone as a class effect, but that is incidental to its intended use. It is investigational and not approved.

Targets: GHSR.

Origin: Synthetic ghrelin-mimetic pentapeptide.

## Properties

- Molecular formula: C43H50N8O5S
- Molecular weight: 790.97 g/mol
- CAS number: 661472-41-9
- Half-life: Not firmly established in public sources; studied as short-acting sc peptide
- Studied routes: Subcutaneous

## Evidence

- Evidence level: Clinical Trial Evidence
- Highest documented: Controlled human trials
- Human trials: 4
- Controlled human trials: 4
- Preclinical sources: 0
- Latest source: 2017

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. Gastroenterology. 2017. 2017. Controlled human trial. Population: Adults with diabetes and moderate to severe gastroparesis symptoms (n=393). Core symptoms and composite score fell versus placebo at all doses; gastric emptying faster; vomiting frequency not significantly different from placebo; worse glucose control in 14.5% [Source](https://pubmed.ncbi.nlm.nih.gov/28760384/)
2. NCT03285308 — A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01. Controlled human trial. Population: Adults with diabetic gastroparesis (n=336). Terminated; the registry reason is that the relamorelin programme was being terminated solely based on a business decision. Results are posted on ClinicalTrials.gov and not summarised here [Source](https://clinicaltrials.gov/study/NCT03285308)
3. NCT01571297 — Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis. Controlled human trial. Population: Adults with diabetic gastroparesis (n=204). Gastric emptying time (primary outcome); results not posted on ClinicalTrials.gov [Source](https://clinicaltrials.gov/study/NCT01571297)
4. A randomized trial of relamorelin for constipation in Parkinson's disease (MOVE-PD): Trial results and lessons learned. Parkinsonism Relat Disord. 2017. 2017. Controlled human trial. Population: People with Parkinson's disease and chronic constipation (18 of an intended 56 completed). Recruitment goals were not met, so no benefit could be shown [Source](https://pubmed.ncbi.nlm.nih.gov/28237854/)

### Registered trials

- [NCT03285308](https://clinicaltrials.gov/study/NCT03285308)
- [NCT01571297](https://clinicaltrials.gov/study/NCT01571297)

## Safety

Side effects: Hyperglycemia; Hunger; GI effects.

Risks: Not approved; WADA S2 (GHS).

Human safety basis: Clinical trial reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

Relamorelin has been studied under an Investigational New Drug application. It is not approved for marketing.

- FDA status: Investigational New Drug (IND)
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is Relamorelin?

Investigational pentapeptide ghrelin receptor agonist developed principally for its gastrointestinal rather than endocrine effects. Ghrelin receptors on enteric neurons accelerate gastric emptying when activated, and relamorelin has been studied mainly in diabetic gastroparesis, where delayed emptying drives the symptoms. Clinical development has been mixed and it is not FDA-approved for any indication.

### How does Relamorelin work?

Relamorelin is a synthetic pentapeptide agonist at growth hormone secretagogue receptor 1a, developed principally for its gastrointestinal rather than endocrine activity. Ghrelin receptors are expressed on enteric neurons, and their activation accelerates gastric emptying and increases antral contractility.

### Is Relamorelin FDA approved?

No. Relamorelin is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.

### What is the half-life of Relamorelin?

Reported half-life for Relamorelin is Not firmly established in public sources; studied as short-acting sc peptide. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Relamorelin banned in sport?

Relamorelin is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to Relamorelin?

Compounds most often compared with Relamorelin include MK-677, Macimorelin, Anamorelin and Tabimorelin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [A randomized trial of relamorelin for constipation in Parkinson's disease (MOVE-PD): Trial results and lessons learned — Parkinsonism Relat Disord, 2017](https://pubmed.ncbi.nlm.nih.gov/28237854/)
- [Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study — Gastroenterology, 2017](https://pubmed.ncbi.nlm.nih.gov/28760384/)
- [Relamorelin in Gastroparesis and Diabetic Gastroparesis: A Meta-Analysis on Its Efficacy and Safety — Cureus, 2023](https://pubmed.ncbi.nlm.nih.gov/38058346/)
- [Pharmacological Approaches to Diabetic Gastroparesis: A systematic review of randomised clinical trials — Sultan Qaboos Univ Med J, 2019](https://pubmed.ncbi.nlm.nih.gov/31897312/)
- [Relamorelin for the treatment of gastrointestinal motility disorders — Expert Opin Investig Drugs, 2017](https://pubmed.ncbi.nlm.nih.gov/28847163/)
